Medication Errors During Treatment with New Oral Anticancer Agents: Consequences for Clinical Practice Based on the AMBORA Study

Abstract

The foundation was not involved in clinical study design, data collection, data analysis or interpretation.

An Easily Expandable Multi-Drug LC-MS Assay for the Simultaneous Quantification of 57 Oral Antitumor Drugs in Human Plasma

“…Concurrent administration of CYP3A4 inhibitors (e.g., clarithromycin), nutrition (e.g., grapefruit-products), or herbal medicines (e.g., St. John’s Wort) can alter pharmacokinetics of oral anticancer drugs in a clinically relevant manner [ 21 ]. An analysis of medication errors in 202 patients treated with oral anticancer drugs illustrated that 47% of all detected medication errors involving these drugs had the potential to affect oral anticancer drug-pharmacokinetics [ 22 ]. Approximately half of these errors were caused by the patients [ 22 ].…”

“…An analysis of medication errors in 202 patients treated with oral anticancer drugs illustrated that 47% of all detected medication errors involving these drugs had the potential to affect oral anticancer drug-pharmacokinetics [ 22 ]. Approximately half of these errors were caused by the patients [ 22 ].…”

Ökonomische Aspekte bei der Versorgung von Patient*innen mit neuen oralen Tumortherapeutika: Erkenntnisse aus der AMBORA-Studie

“…Haupteinschlusskriterium war der Therapiebeginn mit einem neuen oralen Tumortherapeutikum (Zulassung in Deutschland nach Capecitabin im Februar 2001) unabhängig von der Tumorentität. Weitere Details zur AMBORA-Studie wurden bereits veröffentlicht [10,11].…”

New Oral Antitumor Drugs and Medication Safety in Uro-Oncology: Implications for Clinical Practice Based on a Subgroup Analysis of the AMBORA Trial

“…This analysis is based on the dataset of our previously published randomized, controlled, multicenter AMBORA trial [ 13 , 14 ] (Medication Safety with Oral Antitumor Therapy) and targets the subgroup of patients with PC or RCC in more detail. In brief, the AMBORA trial investigated the impact of an intensified clinical pharmacological/pharmaceutical care program on medication safety in 202 patients treated with new OAT independent of tumor entities.…”

“…An intensified clinical pharmacological/pharmaceutical care program added and integrated into the standard of care practice can considerably optimize the use of a broad range of approved new OAT as we could show in the recently published randomized AMBORA trial [ 13 ]. The systematic data collection and analysis using standard operating procedures within the AMBORA trial guaranteed almost complete demographic and medication data of excellent quality (e.g., advanced medication reviews, predefined time points over 12 weeks, consideration of the complete medication, see [ 14 ]). The trial results evidenced that medication errors, side effects, and patient-reported outcomes were significantly improved by an intensified clinical pharmacological/pharmaceutical care program compared to the usual standard of care.…”